Lenacapavir for PrEP Demonstrates Strong Efficacy in Second Phase 3 Trial
Drug Topics
SEPTEMBER 13, 2024
Gilead said data from the study will support global regulatory filings that the company plans to begin by the end of the year.
Fri.Sep 13, 2024
211 
New Frontiers in Technology: AI Use in Clinical Trial Patient Recruitment in Health Systems
Pharmacy Times
SEPTEMBER 13, 2024
AI is significantly enhancing the efficiency of identifying and enrolling patients.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Discussing the Current Landscape of PBM Reform Legislation
Drug Topics
SEPTEMBER 13, 2024
During an interview, Joseph Shields of TransparencyRx discusses the PBM legislation that is expected to move forward in Congress in the next few months.
Experts Develop Multimodal Approach for Treating Long COVID, Other Post-Acute Infectious Syndromes
Pharmacy Times
SEPTEMBER 13, 2024
In the absence of a common treatment for long COVID, researchers from around the world documented the best currently available therapies.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Visual Art Therapy Significantly Improved Patients’ Mental Health Outcomes
Drug Topics
SEPTEMBER 13, 2024
Researchers conducted a meta-analysis detailing previous patient outcomes in response to visual art therapy interventions.
Navigating Pharmacy School: Tips for Success
Pharmacy Is Right For Me
SEPTEMBER 13, 2024
Written by: Toni Mikhael, PharmD, Touro College of Pharmacy Class of 2024. PGY-1 Pharmacy Resident, WellSpan Ephrata Community Hospital, Ephrata, PA Edited by: Anastasiya Shor, PharmD, BCPS Pharmacy school is a challenging but rewarding journey. As students embark on this demanding path, it becomes crucial to equip themselves with a toolkit for success.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Japan approves updated Covid-19 vaccine to tackle JN.1 variant
Pharmaceutical Technology
SEPTEMBER 13, 2024
Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a planned October 2024 Covid-19 vaccination campaign.
STAT+: A new drug offers a rare option for brain cancer treatment — and inspires hopes for more
STAT
SEPTEMBER 13, 2024
For more cancer coverage, sign up for STAT’s pop-up newsletter focused on this weekend’s European Society for Medical Oncology conference, one of the biggest oncology meetings of the year. Details here. When Rachel Guberman found out she had brain cancer, she did so much reading and Googling about the disease that she joked she had reached the end of the internet.
Remote Interventions From Pharmacists Shown to Improve Blood Glucose Control for Type 2 Diabetes
Pharmacy Times
SEPTEMBER 13, 2024
Data show the value of the pharmacist is clear for patients with type 2 diabetes, as their role can have a significant impact on reductions in hemoglobin A1c.
STAT+: Insurers went all-in on Medicare Advantage. Now, some are scaling backÂ
STAT
SEPTEMBER 13, 2024
For years, health insurers battled to gain market share in the lucrative privatized Medicare program. Now, the opposite is true. Some of the companies say they designed their 2025 plans with an eye toward ditching members. Health insurance has always been cyclical — companies go all-in on certain business lines when they’re profitable and get out when they’re not — but next year will mark a particularly drastic turning point for Medicare Advantage , the form of
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
FDA Authorizes OTC Hearing Aid Software Compatible With Apple AirPods
Pharmacy Times
SEPTEMBER 13, 2024
The Hearing Aid Feature can be customized to the user’s needs by amplifying sounds for individuals 18 years or older who have perceived mild to moderate hearing impairments.
UTHealth Houston collaborates with OpenAI to offer clinicians HIPAA-compliant ChatGPT solutions
Fierce Healthcare
SEPTEMBER 13, 2024
UTHealth Houston unveiled a partnership with OpenAI on Friday to build and deploy algorithms for use in medical training and at the patient’s bedside. | UTHealth Houston, an academic medical center in Texas, is partnering with OpenAI to give clinicians, faculty and students access to ChatGPT tools to build custom, HIPAA-compliant AI solutions.
HIV Infections Significantly Reduced With Twice-Yearly Lenacapavir in Cisgender Men, Gender-Diverse Participants
Pharmacy Times
SEPTEMBER 13, 2024
These results build off the PURPOSE 1 trial, contributing to the wealth of evidence surrounding lenacapavir’s positive effects in patients with HIV.
STAT+: Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target
STAT
SEPTEMBER 13, 2024
BARCELONA, Spain — A targeted immunotherapy being developed by the biotech iTeos Therapeutics and GSK delivered promising response rates in patients with a type of lung cancer, propelling the treatment into a pivotal Phase 3 trial and adding fuel to a broader debate about the validity of the target. The companies reported on Saturday that their combination of a TIGIT-targeting antibody and GSK’s Jemperli increased the percentage of patients who saw their tumors shrink versus those
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Investigators Link Early Cholesterol Exposure With Faster Atherosclerosis Development
Pharmacy Times
SEPTEMBER 13, 2024
Exposure to high cholesterol levels is a significant risk factor for atherosclerosis cardiovascular disease.
Opinion: Compounded semaglutide is an ill-defined public health crisis
STAT
SEPTEMBER 13, 2024
I first met Jane (not her real name, of course) on a Friday afternoon in our clinic. She was referred for further evaluation of her chest pain, which, in the context of her family history of early-onset heart attacks and her morbid obesity, understandably concerned her primary care doctor. In the exam room, we dissected her symptoms and decided we’d investigate them further with a stress test.
FDA Approves Ocrevus Zunovo for 2 Forms of Multiple Sclerosis
Pharmacy Times
SEPTEMBER 13, 2024
The approval marks the first and only twice yearly, health care professional-administrated injection for both forms of multiple sclerosis (MS).
STAT+: FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug
STAT
SEPTEMBER 13, 2024
Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for an injectable version of its blockbuster multiple sclerosis therapy Ocrevus, cutting down the time needed to treat patients and potentially staving off growing competition. The approval was driven by the results of a late-stage trial , OCARINA II, in which the company showed that delivering Ocrevus as a 10-minute injection beneath the skin worked as well as the current approach, an hours-long intravenous in
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Study Finds Comparable Risk of Secondary Malignancies in CAR T-Cell Therapy and Standard Treatments
Pharmacy Times
SEPTEMBER 13, 2024
Researchers suggest prior treatments and follow-up duration may play a larger role.
Mercer: Employer benefit costs set to rise by more 5% in 2025 for 3rd straight year
Fierce Healthcare
SEPTEMBER 13, 2024
Employers are bracing for a third straight year with health benefit costs increasing more than 5%, according to a new report from Mercer. | Employers are bracing for a third straight year with health benefit cost increases of more than 5%, according to a new report from Mercer.
After delay, Roche's Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug
Fierce Pharma
SEPTEMBER 13, 2024
It’s better late than never for an FDA approval for the first subcutaneous PD-L1 inhibitor, which was doled out to Roche’s Tecentriq Hybreza after manufacturing delays derailed the company's initia | The under-the-skin formulation trims administration time down to seven minutes compared to the 30 to 60 minutes needed for intravenous Tecentriq.
West Tennessee Healthcare President, CEO James Ross dies
Fierce Healthcare
SEPTEMBER 13, 2024
James Ross, president and CEO of West Tennessee Healthcare, died Thursday morning, according to an announcement from the health system on social media. | The nurse-executive had been with the seven-hospital nonprofit for nearly four decades and was a prominent member of the Jackson, Tennessee, community.
A Pharmacist’s Guide to Medical Cannabis Interactions and Patient Care
Pharmacy Times
SEPTEMBER 13, 2024
As access becomes easier, pharmacists are more likely to encounter questions.
Into the unknown: How quickly can vaccines be developed for Disease X
Pharmaceutical Technology
SEPTEMBER 13, 2024
R&D frameworks are in place for the next pandemic-causing pathogen, but ways to derisk development are unclear.
Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus
Fierce Pharma
SEPTEMBER 13, 2024
When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | The day after Roche gained an FDA approval for its subcutaneous version of cancer drug Tecentriq, the company also scored with a U.S. nod for its under-the-skin formulation of mega-blockbuster multiple sclerosis drug Ocrevus. The approval gives patients a more convenient injected way to receive Ocrevus as opposed to the infused formulation.
Can GLP-1 drugs help with type 1 diabetes?
STAT
SEPTEMBER 13, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, and congratulations on making it through another week. What’s been helping me get through this week is this baby hippo in Thailand called Moo Deng (which apparently translates to Bouncy Pig). She is very likely the cutest and most relatable animal I’ve ever seen.
ESMO: AZ, Daiichi build case for Enhertu in breast cancer patients with brain metastases
Fierce Pharma
SEPTEMBER 13, 2024
Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the medicine’s worth in patients whose cancer has spread to the b | To bolster Enhertu's case in HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo have rolled out positive data for the antibody-drug conjugate in patients who have brain metastases.
Lawmakers scrutinize sluggish efforts to overhaul organ transplants as HHS aims to expand access for HIV-positive patients
Fierce Healthcare
SEPTEMBER 13, 2024
Lawmakers scrutinize sluggish efforts to overhaul organ transplants as HHS aims to expand access for HIV-positive patients dmuoio Fri, 09/13/2024 - 17:08
ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value added from new cancer approvals
Fierce Pharma
SEPTEMBER 13, 2024
ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value added from new cancer approvals kdunleavy Fri, 09/13/2024 - 07:38
Reducing drug shortages: The power of AI in pharma supply chain management
pharmaphorum
SEPTEMBER 13, 2024
AI-driven solutions are revolutionising the pharmaceutical supply chain management process, particularly in reducing drug shortages. Learn more about the power of AI in this field.
ESMO: GSK's Zejula misses survival goal in first-line ovarian cancer, as Pharma&'s combo disappoints
Fierce Pharma
SEPTEMBER 13, 2024
In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final analysis of a phase 3 trial. | In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final analysis of a phase 3 trial. Another study showed that Pharma&’s attempt to enhance its Rubraca with Bristol Myers Squibb’s Opdivo seriously backfired.
Payer Roundup—Minnesota providers drops Humana MA plans; New No Surprises Act bill introduced
Fierce Healthcare
SEPTEMBER 13, 2024
Below is a roundup of payer-centric news headlines you may have missed during the month of September 2024. | This month, Humana faces consequences for prior auth delays, Congress members have introduced new No Surprises Act legislation targeting insurers and Aetna has been sued for denying gender-affirming facial reconstruction surgeries.
The news from ESMO: The latest on anti-TIGIT data, a PD-(L)1 injection, and more
STAT
SEPTEMBER 13, 2024
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here. One of the big presentations of this year’s ESMO (at least in our view) comes tomorrow morning bright and early. David Spigel of Sarah Cannon Research Institute in Nashville will unveil results from the GALAXIES Lung-201 study of an anti-TIGIT therapy from iTeos Therapeutics and GSK in non
Let's personalize your content